{"id":"nct:NCT07760948","kind":"trial","title":"HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide","authors":["Vanderbilt University Medical Center"],"author_count":1,"year":2026,"published":"2026-08-12","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07760948","source_url":"https://clinicaltrials.gov/study/NCT07760948","archive_url":"https://space-kitty.com/papers/nct:NCT07760948","updated":"2026-08-28","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This randomized, double-blind, placebo-controlled trial will evaluate whether daily calcium beta-hydroxy-beta-methylbutyrate (calcium-HMB) plus vitamin D3 preserves muscle mass, physical function, and resting metabolism in adults aged 65 to 85 years with type 2 diabetes who are newly starting semaglutide as part of usual clinical care. Participants will receive calcium-HMB plus vitamin D3 or matching placebo for approximately 6 months. The primary outcome is change in appendicular lean mass measured by dual-energy X-ray absorptiometry from baseline to month 6. Secondary assessments include body composition, muscle strength, physical performance, gait, physical activity, resting metabolic rate, metabolic measures, and whole-body quantitative computed tomography. An optional mechanistic substudy of up to 36 participants will include D3-creatine dilution, nonradioactive stable isotope infusions, repeated blood sampling, a standardized meal, breath sampling, and vastus lateralis muscle biopsies at baseline and month 6.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Type 2 Diabetes Mellitus (T2DM)","Sarcopenia","Obesity","Muscle Loss","Older Adults"],"details":{"acronym":"PRESERVE-HMB","status":"NOT_YET_RECRUITING","phase":"PHASE2","study_type":"INTERVENTIONAL","enrollment":90,"sponsor":"Vanderbilt University Medical Center","conditions":["Type 2 Diabetes Mellitus (T2DM)","Sarcopenia","Obesity","Muscle Loss","Older Adults"],"interventions":["DIETARY_SUPPLEMENT: Calcium-HMB Plus Vitamin D3","OTHER: Matching placebo"],"start_date":"2026-12-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-11-30","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[]}